Brief: PAVmed And Lucid Diagnostics Provide Strategic Business Update

PAVmed

17/01/2023 21:12

Jan 17 (Reuters) - PAVmed Inc  PAVM.O :
    * PAVMED AND LUCID DIAGNOSTICS PROVIDE STRATEGIC BUSINESS
UPDATE
    * PAVMED INC - HAVE IMPLEMENTED A WORKFORCE REDUCTION OF
APPROXIMATELY 20 PERCENT
    * PAVMED INC - COST-CUTTING MEASURES WHICH SEEK TO LOWER
QUARTERLY
CASH BURN BY AT LEAST 25 PERCENT
    * PAVMED INC - LUCID TO PAUSE FURTHER DEVELOPMENT OF ESOCURE
ESOPHAGEAL ABLATION DEVICE
    * PAVMED INC -  LUCID PLANS TO DELAY COMPLETION OF ESOGUARD
BE-2
STUDY TO SECOND HALF OF 2023
    * PAVMED INC - VERIS PLANS TO DELAY DEVELOPMENT AND
REGULATORY
SUBMISSION OF IMPLANTABLE PHYSIOLOGIC MONITOR TO SECOND HALF OF
2023
    * PAVMED INC - PAVMED PLANS TO INDEFINITELY PAUSE OR HALT
ALL
OTHER PRODUCT DEVELOPMENT ACTIVITIES INCLUDING CARPX, PORTIO AND
NEXTFLO
    * PAVMED INC - PAVMED PLANS TO PURSUE ADDITIONAL
COST-CUTTING
INITIATIVES INCLUDING NOT PAYING ANNUAL CASH BONUSES

Source text for Eikon:  ID:nBw9Zq49Qa 
Further company coverage:  PAVM.O 
 ((Reuters.Briefs@thomsonreuters.com;))